|
|||||
|
|
| 肾移植受者应用霉酚酸酯的合理治疗窗 | |
| 引用本文： | 于立新,周敏捷,罗敏.肾移植受者应用霉酚酸酯的合理治疗窗[J].南方医科大学学报,2014,34(12):1842-1845. |
| 作者姓名： | 于立新 周敏捷 罗敏 |
| 作者单位： | 南方医科大学南方医院器官移植科,广东 广州,510515 |
| 基金项目： | 国家自然科学基金(81350009，81450032)；广东省科技计划项目(2012B031800470) Supported by National Natural Science Foundation of China |
| 摘 要： | 目的确定肾脏移植受者应用霉酚酸酯（MMF）的合理治疗窗浓度。方法选取110例肾移植受者分别于术后1月内、2~3 个月、>4个月应用酶放大免疫分析技术测定口服MMF（分两次服用，间隔12 h）12 h后全血谷浓度（即MPA-C0），并观察受者用 药期间急性排斥反应及药物毒副反应发生情况，对所有受者随访时间均为1年。结果统计资料显示，术后急性排斥反应发生 率为13.64%（15/110），药物毒副反应发生率为32.73%（36/110），其中白细胞减少症12例，MMF相关性腹泻10例，感染10例，肝 功能损害4例。发生急性排斥反应受者予甲基强的松龙冲击治疗后均成功逆转，药物毒副反应受者经治疗和（或）调整MMF剂 量后病情恢复，无死亡病例及移植肾摘除病例。通过ROC曲线计算得出，MPA-C0控制在1.40~2.80 mg/L可较好避免肾移植术 后急性排斥反应并减少受者的药物毒副反应。结论对肾移植术后服用MMF的受者进行MPA-C0监测，对MMF用量进行个体 化调整，有利于预防急性排斥反应和药物毒副反应发生，减少并发症，提高移植肾及受者的存活率。 |
| 关 键 词： | 肾移植 霉酚酸酯 谷浓度 治疗窗 |
Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation |
|
| YU Lixin , ZHOU Minjie , LUO Min.Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation[J].Journal of Southern Medical University,2014,34(12):1842-1845. | |
| Authors: | YU Lixin ZHOU Minjie LUO Min |
| Abstract: | Objective To determine the optimal dose range (therapeutic window) of mycophenolate mofetil (MMF) for preventing acute graft rejection following renal transplantation. Methods The trough concentration of MMF (MPA-C0) at 12 h after oral administration of the drug (two doses daily given at an interval of 12 h) was monitored in 110 renal transplant recipients within a month, in 2-3 months, and over 4 months after the transplantation using EMIT method. The occurrence of acute graft rejection and drug toxicity were observed in all the patients during the one-year follow-up. Results The incidence of acute graft rejection after transplantation was 13.64% (15/110) in these patients. Drug toxicity and complications occurred in 32.73% (36/110) of the patients, including 12 cases with reduced white blood cell counts, 10 with MMF cid-associated diarrhea, 10 with infection, 4 with liver function damage. Acute rejection was successfully reversed after methylprednisolone treatment and drug toxicity was managed by corresponding treatment and adjustment of MMF dose. No deaths or graft removal occurred in these patients. The ROC curve showed that a MPA-C0 of 1.40-2.80 mg/L was optimal in preventing acute rejection after the transplantation and reducing adverse drug effects. Conclusion Monitoring MPA-C0 and individualized MMF dosing help to prevent acute graft rejection, reducing drug toxicity and complications, and improving graft survival rate after renal transplantation. |
| Keywords: | renal transplantation mycophenolate mofetil trough concentration moderate dose |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |
| 点击此处可从《南方医科大学学报》浏览原始摘要信息 | |
| 点击此处可从《南方医科大学学报》下载全文 | |
